Jacob P. Laubach
Elite in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Jacob P. Laubach

Oncology | Hematology
Brigham and Women’s Hospital
Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
450 Brookline Avenue, 
Boston, MA 
Offers Telehealth
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Brigham and Women’s Hospital
Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
450 Brookline Avenue, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jacob Laubach is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Laubach is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 181 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 1 clinical trial in the study of Relapsed Refractory Multiple Myeloma (RRMM).

Graduate Institution
Duke University School Of Medicine, 1999
Residency
Duke University Medical Center-GME, 2002
Specialties
Oncology
Hematology
Licenses
Internal Medicine in NC
Board Certifications
Hematology
Internal Medicine
Medical Oncology
Fellowships
Duke University Medical Center-GME, 2008
Hospital Affiliations
Massachusetts General Hospital
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Community Health Options
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
450 Brookline Avenue, Boston, MA 02115
Call: 617-632-4218

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 2
Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drugs: ACE-011, Lenalidomide, Dexamethasone, Pomalidomide
Study Phase: Phase 1
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug, Procedure
Study Drugs: Bortezomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 06, 2026
Intervention Type: Drug
Study Drugs: Ibrutinib, Lenalidomide, Dexamethasone
Study Phase: Phase 1
Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drugs: Isatuximab, Lenalidomide, Bortezomib Injection, Dexamethasone
Study Phase: Phase 2
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug
Study Drugs: Panobinostat Capsules, Bortezomib Injection, Dexamethasone Tablets
Study Phase: Phase 2
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 05, 2021
Intervention Type: Drug
Study Drugs: Panobinostat, Dexamethasone, Lenalidomide, Bortezomib
Study Phase: Phase 1
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: November 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Enrollment Status: Withdrawn
Publish Date: August 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Enrollment Status: Completed
Publish Date: March 16, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 9 Less Clinical Trials

185 Total Publications

Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Journal: Expert opinion on emerging drugs
Published: October 30, 2025
View All 185 Publications
Similar Doctors
Paul G. Richardson
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Paul G. Richardson
Hematology Oncology | Oncology | Hematology
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Paul G. Richardson
Hematology Oncology | Oncology | Hematology

Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center

450 Brookline Avenue, 
Boston, MA 
 (0.1 miles away)
617-632-2104
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Richardson is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Richardson is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Graft.

Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Noopur S. Raje
Hematology | Oncology
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Noopur S. Raje
Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Noopur Raje is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Raje is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Her top areas of expertise are Multiple Myeloma, Plasmacytoma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Vertebroplasty. Dr. Raje is currently accepting new patients.

Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Andrew J. Yee
Hematology Oncology | Hematology | Oncology
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Andrew J. Yee
Hematology Oncology | Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Yee is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Yee is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Vertebroplasty, and Bone Marrow Aspiration. Dr. Yee is currently accepting new patients.

VIEW MORE RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Laubach's expertise for a condition
ConditionClose
  • Elite
  • Multiple Myeloma
    Dr. Laubach is
    Elite
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Relapsed Refractory Multiple Myeloma (RRMM)
    Dr. Laubach is
    Elite
    . Learn about Relapsed Refractory Multiple Myeloma (RRMM).
    See more Relapsed Refractory Multiple Myeloma (RRMM) experts
  • Smoldering Multiple Myeloma
    Dr. Laubach is
    Elite
    . Learn about Smoldering Multiple Myeloma.
    See more Smoldering Multiple Myeloma experts
  • Distinguished
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
    Dr. Laubach is
    Distinguished
    . Learn about Monoclonal Gammopathy of Undetermined Significance (MGUS).
    See more Monoclonal Gammopathy of Undetermined Significance (MGUS) experts
  • Plasmacytoma
    Dr. Laubach is
    Distinguished
    . Learn about Plasmacytoma.
    See more Plasmacytoma experts
  • Primary Amyloidosis
    Dr. Laubach is
    Distinguished
    . Learn about Primary Amyloidosis.
    See more Primary Amyloidosis experts
  • Schnitzler Syndrome
    Dr. Laubach is
    Distinguished
    . Learn about Schnitzler Syndrome.
    See more Schnitzler Syndrome experts
  • Waldenstrom Macroglobulinemia
    Dr. Laubach is
    Distinguished
    . Learn about Waldenstrom Macroglobulinemia.
    See more Waldenstrom Macroglobulinemia experts
  • Advanced
  • Bone Marrow Transplant
    Dr. Laubach is
    Advanced
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Cardiac Amyloidosis
    Dr. Laubach is
    Advanced
    . Learn about Cardiac Amyloidosis.
    See more Cardiac Amyloidosis experts
  • Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
    Dr. Laubach is
    Advanced
    . Learn about Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency.
    See more Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency experts
  • GTP Cyclohydrolase 1 Deficiency
    Dr. Laubach is
    Advanced
    . Learn about GTP Cyclohydrolase 1 Deficiency.
    See more GTP Cyclohydrolase 1 Deficiency experts
  • Pseudocholinesterase Deficiency
    Dr. Laubach is
    Advanced
    . Learn about Pseudocholinesterase Deficiency.
    See more Pseudocholinesterase Deficiency experts
  • Thrombocytopenia
    Dr. Laubach is
    Advanced
    . Learn about Thrombocytopenia.
    See more Thrombocytopenia experts
  • Experienced
  • Agranulocytosis
    Dr. Laubach is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Blood Clots
    Dr. Laubach is
    Experienced
    . Learn about Blood Clots.
    See more Blood Clots experts
  • Bone Marrow Aspiration
    Dr. Laubach is
    Experienced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
  • Cerebral Amyloid Angiopathy
    Dr. Laubach is
    Experienced
    . Learn about Cerebral Amyloid Angiopathy.
    See more Cerebral Amyloid Angiopathy experts
  • Chronic Familial Neutropenia
    Dr. Laubach is
    Experienced
    . Learn about Chronic Familial Neutropenia.
    See more Chronic Familial Neutropenia experts
  • Cryoglobulinemia
    Dr. Laubach is
    Experienced
    . Learn about Cryoglobulinemia.
    See more Cryoglobulinemia experts
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.